Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Cash from Financing Activities (2021 - 2025)

PAVmed has reported Cash from Financing Activities over the past 5 years, most recently at -$2000.0 for Q3 2025.

  • Quarterly results put Cash from Financing Activities at -$2000.0 for Q3 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $5.6 million (down 84.6% YoY), and the annual figure for FY2025 was $5.6 million, down 82.13%.
  • Cash from Financing Activities for Q3 2025 was -$2000.0 at PAVmed, down from $2.5 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for PAVM hit a ceiling of $60.1 million in Q4 2021 and a floor of -$2000.0 in Q3 2025.
  • Median Cash from Financing Activities over the past 5 years was $2.8 million (2025), compared with a mean of $11.7 million.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 99.87% in 2022 and later surged 7787.34% in 2023.
  • PAVmed's Cash from Financing Activities stood at $60.1 million in 2021, then plummeted by 99.87% to $80000.0 in 2022, then soared by 6510.0% to $5.3 million in 2023, then tumbled by 93.76% to $330000.0 in 2024, then plummeted by 100.61% to -$2000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were -$2000.0 (Q3 2025), $2.5 million (Q2 2025), and $3.1 million (Q1 2025) per Business Quant data.